Furthermore, low HNF3β expression was detected in 0/5 stage 0, 10/24 (41.67%) stage I, 21/49 (42.86%) stage II, 58/87 (66.67%) stage III, and 9/9 (100%) stage IV patients (Figure 1Ba,b), showing a trend toward decreased HNF3β expression in advanced tumor stages (III and IV; P = 0.0012). This evidence concerns the gene FOXA2 and neoplasm.